By Fineline Cube 
China-based Minghui Pharmaceutical Inc. announced the successful completion of a $131 million Pre-IPO financing round. The round was led by OrbiMed, a renowned global healthcare investment firm, and co-led by Qiming Venture Partners. Existing shareholder TF Capital continued its support, and the company also brought in several high-quality institutional investors, including BioTrack Capital, 5Y Capital, New Day Fund, and Wider Link Enterprise Investment Limited. Representatives from OrbiMed and Qiming Venture Partners will join the company’s board of directors.
Funding Utilization
The funds raised will primarily be used to accelerate the development of the company’s core clinical-stage programs. A key focus will be on advancing the combination therapy strategy of its PD-1/VEGF bispecific antibody and antibody-drug conjugates (ADCs). The capital will also support the launch preparations and commercialization of the topical JAK inhibitor in China.-Fineline Info & Tech